Paper Details

  1. Home
  2. Paper Details

Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR).

Author: BurgerDavid M, RockstrohJuergen K, SchneiderKatrin, WasmuthJan-Christian, la PorteCharles J L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Reduced dosages of twice daily indinavir (IDV) boosted by low-dose ritonavir (RTV) can significantly lower IDV exposure, but tolerability is lower at higher IDV doses. Therapeutic drug monitoring is recommended to optimize drug levels and minimize toxicity.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To assess the pharmacokinetics and tolerability of reduced dosages of twice daily indinavir (IDV) boosted by low-dose ritonavir (RTV) in healthy volunteers. METHODS: Pharmacokinetics and tolerability of IDV/RTV twice daily (600/100 mg and 400/100 mg) were assessed in a randomized crossov...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15134183

データ提供：米国国立医学図書館（NLM）

Indinavir/Ritonavir: A Balancing Act for HIV Treatment

The fight against HIV infection is a continuous endeavor, and the development of effective antiretroviral therapies is a cornerstone of this struggle. This study, published in the journal Antiviral Therapy, examines the pharmacokinetics and tolerability of two reduced-dose regimens of indinavir (IDV) boosted by ritonavir (RTV) in healthy volunteers.

The researchers investigated the pharmacokinetic profiles and tolerability of IDV/RTV 600/100 mg twice daily and IDV/RTV 400/100 mg twice daily. They found that reducing the IDV dose resulted in significantly lower drug exposure. However, the study also revealed that tolerability was lower in the 600 mg IDV group. This suggests that individual drug monitoring may be crucial to ensure adequate drug levels while minimizing toxicity.

A Balancing Act: Minimizing Toxicity While Maintaining Efficacy

This study highlights the importance of individualizing treatment regimens for HIV infection. The findings suggest that adjusting drug dosages based on individual pharmacokinetic profiles can help optimize treatment efficacy while minimizing side effects. This underscores the need for personalized care and close monitoring to ensure the best possible outcomes for patients living with HIV.

Navigating the Desert of HIV Treatment: A Journey of Collaboration

Living with HIV requires ongoing management and close collaboration between patients and healthcare providers. This study underscores the importance of personalized treatment strategies and the need for regular monitoring to ensure optimal outcomes. As a seasoned traveler through the vast desert of HIV research, I am encouraged by the advancements in antiretroviral therapy, offering hope and improved quality of life for those living with HIV.

Dr. Camel's Conclusion

This study's exploration of indinavir/ritonavir dosing regimens is a testament to the ongoing quest to optimize HIV treatment strategies. As a fellow explorer in the medical world, I am inspired by the researchers' efforts to find the best ways to combat HIV infection and improve the lives of those affected.

Date :
  1. Date Completed 2004-06-28
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

15134183

DOI: Digital Object Identifier

15134183

Related Literature

Article Analysis
・Side Effects of indinavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.